J&J Brings In Multiple Sclerosis Candidate Via Licensing Pact With Pipeline

 
• By Joseph Haas

Deal Snapshot: Pipeline gets $50m up front and a $25m equity investment in exchange for global rights to an M1 receptor antagonist cleared to move into Phase II in relapsing/remitting MS.

Multiple Sclerosis
J&J adds MS drug candidate in license deal with Pipeline

More from Deals

More from Business